Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: Higher incidence than previously thought

被引:268
作者
Evans, DGR
Moran, T
King, A
Saeed, S
Gurusinghe, J
Ramsden, R
机构
[1] St Marys Hosp, Acad Univ Med Genet, Manchester M13 0JH, Lancs, England
[2] St Marys Hosp, Reg Genet Serv, Manchester M13 0JH, Lancs, England
[3] Univ Manchester, Ctr Canc Epidemiol, Manchester, Lancs, England
[4] Hope Hosp, Dept Neurosurg, Manchester, Lancs, England
[5] Manchester Royal Infirm, Dept Otolaryngol, Manchester M13 9WL, Lancs, England
[6] Royal Preston Hosp, Dept Neurosurg, Preston, Lancs, England
关键词
vestibular schwannoma; incidence; NF2; mosaic; mutations;
D O I
10.1097/00129492-200501000-00016
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To determine the incidence of vestibular schwannoma (VS) in sporadic, neurofibromatosis type 2 (NF2) germline and mosaic form in a 10-year period. Study Design: Review of all incident cases of VS presenting to the four main neurosurgical centers for a population of 4.1 million from 1990 to 1999 and cross-referencing with the regional cancer registry. Setting: Population based. Patients: All patients presenting with VS detected on magnetic resonance imaging scan. Results: A total of 419 sporadic and 64 NF2-related VS were identified over the study period. This represented an incidence of 10.4 per million per year for sporadic VS and 11.8 per million per year including NF2-related tumors. The incidence rose to 14 per million per year in the latter 5 years. The NF2 patient diagnoses represent an estimated birth incidence of 1 in 25,000, and 7% of the patients with VS had NF2, which is higher than previous estimates. Conclusions: The incidence of VS is rising almost certainly due to increasing diagnosis in the magnetic resonance imaging era. At current rates, 1 per 1,000 individuals will be diagnosed with VS in their lifetime. More VS than previously thought are due to NF2, which may be because of recognition of mosaic forms of the disease.
引用
收藏
页码:93 / 97
页数:5
相关论文
共 25 条
[1]  
Baser M. E., 2002, Neurology, V59, P1759
[2]   Predictors of the risk of mortality in neurofibromatosis 2 [J].
Baser, ME ;
Friedman, JM ;
Aeschliman, D ;
Joe, H ;
Wallace, AJ ;
Ramsden, RT ;
Evans, DGR .
AMERICAN JOURNAL OF HUMAN GENETICS, 2002, 71 (04) :715-723
[3]   GERMLINE MUTATIONS IN THE NEUROFIBROMATOSIS TYPE-2 TUMOR-SUPPRESSOR GENE [J].
BOURN, D ;
CARTER, SA ;
MASON, S ;
EVANS, DGR ;
STRACHAN, T .
HUMAN MOLECULAR GENETICS, 1994, 3 (05) :813-816
[4]   VARIATION OF EXPRESSION OF THE GENE FOR TYPE-2 NEUROFIBROMATOSIS - ABSENCE OF A GENDER EFFECT ON VESTIBULAR SCHWANNOMAS, BUT CONFIRMATION OF A PREPONDERANCE OF MENINGIOMAS IN FEMALES [J].
EVANS, DGR ;
BLAIR, V ;
STRACHAN, T ;
LYE, RH ;
RAMSDEN, RT .
JOURNAL OF LARYNGOLOGY AND OTOLOGY, 1995, 109 (09) :830-835
[5]   A GENETIC-STUDY OF TYPE-2 NEUROFIBROMATOSIS IN THE UNITED-KINGDOM .1. PREVALENCE, MUTATION-RATE, FITNESS, AND CONFIRMATION OF MATERNAL TRANSMISSION EFFECT ON SEVERITY [J].
EVANS, DGR ;
HUSON, SM ;
DONNAI, D ;
NEARY, W ;
BLAIR, V ;
TEARE, D ;
NEWTON, V ;
STRACHAN, T ;
RAMSDEN, R ;
HARRIS, R .
JOURNAL OF MEDICAL GENETICS, 1992, 29 (12) :841-846
[6]   Somatic mosaicism: A common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis [J].
Evans, DGR ;
Wallace, AJ ;
Wu, CL ;
Trueman, L ;
Ramsden, RT ;
Strachan, T .
AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 63 (03) :727-736
[7]   Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations [J].
Evans, DGR ;
Trueman, L ;
Wallace, A ;
Collins, S ;
Strachan, T .
JOURNAL OF MEDICAL GENETICS, 1998, 35 (06) :450-455
[8]  
EVANS DGR, 1992, Q J MED, V84, P603
[9]   EPIDEMIOLOGY AND CLINICAL-FEATURES OF VESTIBULAR SCHWANNOMA IN MANITOBA, CANADA [J].
FROHLICH, AM ;
SUTHERLAND, GR .
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1993, 20 (02) :126-130
[10]   The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2 [J].
Gutmann, DH ;
Aylsworth, A ;
Carey, JC ;
Korf, B ;
Marks, J ;
Pyeritz, RE ;
Rubenstein, A ;
Viskochil, D .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 278 (01) :51-57